TY - JOUR
T1 - Racial disparities and socioeconomic status in men diagnosed with testicular germ cell tumors
T2 - A survival analysis
AU - Sun, Maxine
AU - Abdollah, Firas
AU - Liberman, Daniel
AU - Abdo, Al'A
AU - Thuret, Rodolphe
AU - Tian, Zhe
AU - Shariat, Shahrokh F.
AU - Montorsi, Francesco
AU - Perrotte, Paul
AU - Karakiewicz, Pierre I.
PY - 2011/9/15
Y1 - 2011/9/15
N2 - BACKGROUND: Previous reports indicated that African-American men with testicular germ cell tumors (TGCTs) have more aggressive tumor characteristics and less favorable outcomes than other men. The authors of this report evaluated the effects of race and socioeconomic status (SES) on stage distribution, overall mortality (OM), and cancer-specific mortality (CSM) in men with TGCTs. METHODS: The Surveillance, Epidemiology, and End Results (SEER) database was used to identify 22,553 men who were diagnosed with TGCTs between 1988 and 2006. Kaplan-Meier and Cox regression analyses were generated to predict OM and CSM. Covariates of the analyses included race, SES, age, histologic subtype, disease stage, procedure type, SEER registry, and year of diagnosis. The interaction between race and SES also was examined. RESULTS: Overall, there were 516 African-American men, 21,090 Caucasian men, and 947 men of other races. African-Americans (14.9%) and individuals with low SES (10.7%) had a higher proportion of distant stage disease. CSM and OM rates were significantly higher for African-American patients and for patients who resided in low SES counties. Multivariate analyses revealed that African-American men and men with low SES were more likely to die of OM and CSM relative to Caucasian men (P <.001) and men with high SES (P <.001), respectively. The interaction between race and SES was not significant. CONCLUSIONS: African-American race and low SES appeared to predispose men to more advanced disease stages and to higher OM and CSM rates. These observations may warrant race-specific and/or SES-specific adjustments in the treatment of TGCT.
AB - BACKGROUND: Previous reports indicated that African-American men with testicular germ cell tumors (TGCTs) have more aggressive tumor characteristics and less favorable outcomes than other men. The authors of this report evaluated the effects of race and socioeconomic status (SES) on stage distribution, overall mortality (OM), and cancer-specific mortality (CSM) in men with TGCTs. METHODS: The Surveillance, Epidemiology, and End Results (SEER) database was used to identify 22,553 men who were diagnosed with TGCTs between 1988 and 2006. Kaplan-Meier and Cox regression analyses were generated to predict OM and CSM. Covariates of the analyses included race, SES, age, histologic subtype, disease stage, procedure type, SEER registry, and year of diagnosis. The interaction between race and SES also was examined. RESULTS: Overall, there were 516 African-American men, 21,090 Caucasian men, and 947 men of other races. African-Americans (14.9%) and individuals with low SES (10.7%) had a higher proportion of distant stage disease. CSM and OM rates were significantly higher for African-American patients and for patients who resided in low SES counties. Multivariate analyses revealed that African-American men and men with low SES were more likely to die of OM and CSM relative to Caucasian men (P <.001) and men with high SES (P <.001), respectively. The interaction between race and SES was not significant. CONCLUSIONS: African-American race and low SES appeared to predispose men to more advanced disease stages and to higher OM and CSM rates. These observations may warrant race-specific and/or SES-specific adjustments in the treatment of TGCT.
KW - disparities
KW - oncologic outcome
KW - race
KW - socioeconomic status
KW - testicular cancer
UR - http://www.scopus.com/inward/record.url?scp=80052506545&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80052506545&partnerID=8YFLogxK
U2 - 10.1002/cncr.25969
DO - 10.1002/cncr.25969
M3 - Article
C2 - 21387261
AN - SCOPUS:80052506545
SN - 0008-543X
VL - 117
SP - 4277
EP - 4285
JO - Cancer
JF - Cancer
IS - 18
ER -